Danaher (DHR) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Danaher (NYSE: DHR) in the last few weeks:

  • 2/1/2018 – Danaher had its price target raised by analysts at Argus from $100.00 to $115.00. They now have a “buy” rating on the stock.
  • 1/31/2018 – Danaher had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $98.00 price target on the stock.
  • 1/31/2018 – Danaher had its price target raised by analysts at Stifel Nicolaus from $110.00 to $115.00. They now have a “buy” rating on the stock.
  • 1/31/2018 – Danaher had its price target raised by analysts at Morgan Stanley from $103.00 to $110.00. They now have an “overweight” rating on the stock.
  • 1/31/2018 – Danaher had its price target raised by analysts at Credit Suisse Group AG from $99.00 to $105.00. They now have an “outperform” rating on the stock.
  • 1/30/2018 – Danaher had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $110.00 price target on the stock.
  • 1/22/2018 – Danaher is now covered by analysts at UBS Group AG. They set a “buy” rating and a $99.97 price target on the stock.
  • 1/19/2018 – Danaher had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $110.00 price target on the stock.
  • 1/12/2018 – Danaher had its “buy” rating reaffirmed by analysts at Robert W. Baird.
  • 1/4/2018 – Danaher had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $96.00 price target on the stock.
  • 1/3/2018 – Danaher is now covered by analysts at Evercore ISI. They set an “outperform” rating on the stock.
  • 12/19/2017 – Danaher was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past six months, Danaher has outperformed the industry average. We are optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Going forward, the company expects the biopharma business to be a major growth driver. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues. However, on the flip side, sluggish economic conditions across key operating regions and unfavorable currency translations pose as threats. Especially, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.”
  • 12/19/2017 – Danaher had its “hold” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $99.00 price target on the stock.
  • 12/15/2017 – Danaher had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $99.00 price target on the stock.
  • 12/15/2017 – Danaher had its price target raised by analysts at Citigroup Inc to $107.00. They now have a “buy” rating on the stock.

Danaher Co. (NYSE:DHR) opened at $94.46 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Co. has a 52 week low of $78.97 and a 52 week high of $104.82. The company has a market cap of $65,800.84, a PE ratio of 26.76, a price-to-earnings-growth ratio of 1.99 and a beta of 1.04.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.03. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a net margin of 13.60% and a return on equity of 11.36%. Danaher’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 earnings per share. equities analysts predict that Danaher Co. will post 4.37 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is 15.86%.

In other news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the completion of the sale, the executive vice president now directly owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders sold a total of 274,913 shares of company stock worth $27,729,293 over the last three months. Insiders own 12.20% of the company’s stock.

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Receive News & Ratings for Danaher Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply